XNASSKIN
Market cap201mUSD
Jan 16, Last price
1.62USD
1D
4.52%
1Q
1.25%
IPO
-84.07%
Name
Beauty Health Co
Chart & Performance
P/E
—
P/S
0.51
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.98%
Rev. gr., 5y
28.79%
Revenues
398m
+8.78%
Net income
-100m
L
CFO
22m
P
Earnings
Mar 10, 2025
Profile
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
IPO date
Feb 10, 2020
Employees
1,034
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 397,991 8.78% | 365,876 40.68% | ||||
Cost of revenue | 528,908 | 390,156 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (130,917) | (24,280) | ||||
NOPBT Margin | ||||||
Operating Taxes | (1,773) | 648 | ||||
Tax Rate | ||||||
NOPAT | (129,144) | (24,928) | ||||
Net income | (100,116) -326.38% | 44,224 -111.79% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (32,395) | (160,927) | ||||
BB yield | 7.91% | 11.91% | ||||
| Debt | ||||||
Debt current | 9,196 | 4,958 | ||||
Long-term debt | 761,608 | 764,479 | ||||
Deferred revenue | 2,011 | |||||
Other long-term liabilities | 6,322 | 13,462 | ||||
Net debt | 247,779 | 201,240 | ||||
| Cash flow | ||||||
Cash from operating activities | 21,750 | (106,600) | ||||
CAPEX | (13,049) | (17,394) | ||||
Cash from investing activities | (31,507) | (18,869) | ||||
Cash from financing activities | (37,448) | (205,242) | ||||
FCF | (41,098) | (154,038) | ||||
| Balance | ||||||
Cash | 523,025 | 568,197 | ||||
Long term investments | ||||||
Excess cash | 503,125 | 549,903 | ||||
Stockholders' equity | (481,891) | (378,844) | ||||
Invested Capital | 1,304,490 | 1,316,621 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 131,681 | 148,506 | ||||
Price | 3.11 -65.82% | 9.10 -62.33% | ||||
Market cap | 409,527 -69.70% | 1,351,407 -45.22% | ||||
EV | 657,306 | 1,552,647 | ||||
EBITDA | (96,242) | (2,264) | ||||
EV/EBITDA | ||||||
Interest | 13,649 | 13,392 | ||||
Interest/NOPBT | ||||||